Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 28 2019 - 4:30PM
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that
Scott Garland, Portola’s president and chief executive officer,
will present a corporate overview at the following investor
conferences in June:
- William Blair 39th Annual Growth Stock Conference on Thursday,
June 6, 2019, at 3:20 p.m. Central Time in Chicago, IL.
- Goldman Sachs 40th Annual Global Healthcare Conference on
Tuesday, June 11, 2019, at 2:40 p.m. Pacific Time in Rancho Palos
Verdes, CA.
Both presentations will be webcast live and
available for replay in the Investor Relations section of the
Portola website (www.portola.com).
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a global,
commercial-stage biopharmaceutical company focused on the
discovery, development and commercialization of novel therapeutics
that could significantly advance the fields of thrombosis and other
hematologic conditions. The Company’s first two commercialized
products are Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet
alfa), and Bevyxxa® (betrixaban). The company also is
advancing cerdulatinib, a Syk/JAK inhibitor being developed for the
treatment of hematologic cancers. Founded in 2003 in South San
Francisco, California, Portola has operations in the United States
and Europe.
Investor Contact: |
Media Contact: |
Cara Miller |
Pure Communications |
Portola Pharmaceuticals |
Portola_Media@purecommunications.com |
ir@portola.com |
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Sep 2023 to Sep 2024